{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:59:34Z","timestamp":1792454374722,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.beem.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T17:49:29Z","timestamp":1390499369000},"page":"439-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Overcoming toxicity and side-effects of lipid-lowering therapies"],"prefix":"10.1016","volume":"28","author":[{"given":"Michael J.","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke J.","family":"Laffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.01.006_bib1","article-title":"2013 ACC\/AHA Guideline on the treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"9493","key":"10.1016\/j.beem.2014.01.006_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.beem.2014.01.006_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.beem.2014.01.006_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/0003-4819-137-7-200210010-00015","article-title":"Can statins cause chronic low-grade myopathy?","volume":"137","author":"Grundy","year":"2002","journal-title":"Ann Intern Med"},{"issue":"8A","key":"10.1016\/j.beem.2014.01.006_bib5","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.beem.2014.01.006_bib6","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1016\/j.beem.2014.01.006_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2014.01.006_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.beem.2014.01.006_bib9","series-title":"FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs","year":"2012"},{"issue":"9716","key":"10.1016\/j.beem.2014.01.006_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.beem.2014.01.006_bib12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2014.01.006_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.01.006_bib14","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.beem.2014.01.006_bib15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2125.2012.04403.x","article-title":"Statins and risk of treated incident diabetes in a primary care population","volume":"75","author":"Zaharan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.beem.2014.01.006_bib16","first-page":"CD007514","article-title":"Statins for the treatment of dementia","author":"McGuinness","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11883-009-0077-8","article-title":"Management of the patient with statin intolerance","volume":"12","author":"Vandenberg","year":"2010","journal-title":"Curr Atheroscler Rep"},{"issue":"17","key":"10.1016\/j.beem.2014.01.006_bib18","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.beem.2014.01.006_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2013 a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2014.01.006_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","article-title":"Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance","volume":"103","author":"Ruisinger","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.beem.2014.01.006_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.beem.2014.01.006_bib23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins","volume":"101","author":"Gadarla","year":"2008","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2014.01.006_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2014.01.006_bib25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2014.01.006_bib26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/VHRM.S5551","article-title":"Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals","volume":"5","author":"Saito","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/QAI.0b013e318251addb","article-title":"Effects of steady-state lopinavir\/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers","volume":"60","author":"Morgan","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.beem.2014.01.006_bib28","first-page":"912","article-title":"Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group","volume":"81","author":"Fruchart","year":"1998","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.beem.2014.01.006_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"9500","key":"10.1016\/j.beem.2014.01.006_bib30","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.beem.2014.01.006_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1990.03450010075034","article-title":"Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy","volume":"264","author":"Pierce","year":"1990","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.beem.2014.01.006_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"J\u00a0Am Med Assoc"},{"issue":"16","key":"10.1016\/j.beem.2014.01.006_bib36","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"issue":"6A","key":"10.1016\/j.beem.2014.01.006_bib37","doi-asserted-by":"crossref","first-page":"47C","DOI":"10.1016\/j.amjcard.2006.11.022","article-title":"Safety considerations with gastrointestinally active lipid-lowering drugs","volume":"99","author":"Jacobson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.beem.2014.01.006_bib38","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.tips.2011.08.002","article-title":"Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials","volume":"32","author":"Lukasova","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosissup.2012.10.036","article-title":"Nicotinic acid as a lipid-modifying drug \u2013 a review","volume":"14","author":"Julius","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"17","key":"10.1016\/j.beem.2014.01.006_bib40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.beem.2014.01.006_bib41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus","volume":"264","author":"Garg","year":"1990","journal-title":"J\u00a0Am Med Assoc"},{"issue":"5","key":"10.1016\/j.beem.2014.01.006_bib42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J\u00a0Intern Med"},{"issue":"9784","key":"10.1016\/j.beem.2014.01.006_bib43","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beem.2014.01.006_bib44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.beem.2014.01.006_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1749-8546-1-4","article-title":"Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials","volume":"1","author":"Liu","year":"2006","journal-title":"Chin Med"},{"issue":"12","key":"10.1016\/j.beem.2014.01.006_bib46","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","article-title":"Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial","volume":"150","author":"Becker","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","article-title":"Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance","volume":"105","author":"Halbert","year":"2010","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jacl.2012.09.003","article-title":"Review of red yeast rice content and current Food and Drug Administration oversight","volume":"7","author":"Childress","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"issue":"20","key":"10.1016\/j.beem.2014.01.006_bib49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","article-title":"Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance","volume":"61","author":"Larsen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib51","first-page":"11","article-title":"Low serum 25 (OH) vitamin D levels (<32\u00a0ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res \u2013 J Lab Clin Med"},{"issue":"23","key":"10.1016\/j.beem.2014.01.006_bib52","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.beem.2014.01.006_bib53","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.beem.2014.01.006_bib54","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","article-title":"Coenzyme Q(10) and selenium in statin-associated myopathy treatment","volume":"91","author":"Fedacko","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2014.01.006_bib56","first-page":"98","article-title":"The effect of coenzyme Q10 in statin myopathy","volume":"33","author":"Zlatohlavek","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"issue":"9","key":"10.1016\/j.beem.2014.01.006_bib57","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.beem.2014.01.006_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand Cardiovasc J"},{"issue":"3","key":"10.1016\/j.beem.2014.01.006_bib59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2013.02.002","article-title":"A\u00a0randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design","volume":"7","author":"Parker","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"issue":"3","key":"10.1016\/j.beem.2014.01.006_bib60","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yrtph.2006.05.006","article-title":"Risk assessment for coenzyme Q10 (Ubiquinone)","volume":"45","author":"Hathcock","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"issue":"12","key":"10.1016\/j.beem.2014.01.006_bib61","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4065\/78.12.1463","article-title":"Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain","volume":"78","author":"Plotnikoff","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.beem.2014.01.006_bib62","first-page":"487","article-title":"Possible mechanisms of interaction between statins and vitamin D","volume":"105","author":"Bhattacharyya","year":"2012","journal-title":"QJM \u2013 Mon J Assoc Phys"},{"issue":"1","key":"10.1016\/j.beem.2014.01.006_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.beem.2014.01.006_bib64","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1185\/03007995.2011.598144","article-title":"Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance","volume":"27","author":"Glueck","year":"2011","journal-title":"Curr Med Res Opin"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:48:57Z","timestamp":1761497337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X14000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521690X14000220"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.01.006","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming toxicity and side-effects of lipid-lowering therapies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}